Skip to content

GLYCOPYRRONIUM, (2R,3'S)-

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What GLYCOPYRRONIUM, (2R,3'S)- does in the body

Peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated

From the FDA-approved label: Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sinoatrial node, the atrioventricular node, exocrine glands and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · V92SO9WP2I · read 2026-08-29

Where each sentence above came from

No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

No statement of the main limit is recorded.

The four opening statements run to 114 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Postoperative Acute Kidney Injury

The study did not show it

Who was studied
NCT02726620
How many people
22435
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)

The study did not show it

Who was studied
NCT01985334
How many people
4389
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

COPD exacerbation rate

The study did not show it

Who was studied
NCT01911364
How many people
3686
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28

The study did not show it

Who was studied
NCT04320342
How many people
3433
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.

The study did not show it

Who was studied
NCT01120691
How many people
2224
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment

The study did not show it

Who was studied
NCT01202188
How many people
2144
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Injection

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Glycopyrrolate Injection, USP (0.2 mg/mL) is an anticholinergic indicated for use in: anesthesia (all ages) for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation, intraoperatively to counteract surgically or drug-induced or vagal reflex-associated…

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Glycopyrrolate was evaluated for chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling.”

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

  • On older people, the label states: “Clinical studies of glycopyrrolate did not include subjects aged 65 and over.”

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary There are no available data in pregnant women for glycopyrrolate to inform decisions concerning any drug-associated risks.”

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

  • On people with reduced kidney function, the label states: “Because glycopyrrolate is largely renally eliminated, glycopyrrolate should be used with caution in patients with renal impairment [see Clinical Pharmacology ( 12.3 )].”

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Injection

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as injectable, injectable, solution, tablet, given by the injection, injection, oral route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Injection

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 226 products list this as an active ingredient in the United States drug directory. 216 of them contain it and nothing else.

    FDA National Drug Code directory · 71872-7292 · read 2026-08-29

  • They are sold as aerosol, metered, injection, injection, solution, liquid, powder and solution, taken intramuscular, intravenous, oral and respiratory (inhalation).

    FDA National Drug Code directory · 71872-7292 · read 2026-08-29

  • The regulator's established pharmacologic class for it is anticholinergic [epc], cholinergic antagonists [moa] and cholinergic muscarinic antagonist [epc].

    FDA National Drug Code directory · 71872-7292 · read 2026-08-29

  • 121 published labels name it as an active ingredient. 117 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · e76bc0e4-68f5-70b4-e053-2a95a90a451e · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · e76bc0e4-68f5-70b4-e053-2a95a90a451e · read 2026-08-29

  • Glycopyrrolate is oral at 3 DOSAGE FORMS AND STRENGTHS Glycopyrrolate Oral Solution is available as a 1 mg/5 mL clear, cherry-flavored solution for oral administration in 16 ounce (473 mL) bottles. 1 mg/5 mL, oral solution in 16 ounce bottles., recorded as fda label in effect 2022-07-13 in the United States.

    US prescribing information · 4741be85-3abb-4545-aba9-281f64d210ec · read 2026-08-30

  • Recorded price in US: 0.0988–0.1472 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 21 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

  • Recorded price in US: 0.20269–1.48055 USD per one millilitre, across 27 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of GLYCOPYRRONIUM, (2R,3'S)- studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of GLYCOPYRRONIUM, (2R,3'S)- are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 117 documents were read for this substance.

    RNAWiki source record

  • 15 of them state the same bioavailability, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
V92SO9WP2I
RxNorm concept
238212

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Written into the record, not signed off.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 74 approved applications cover products containing this substance. The earliest was NDA012827, approved 19610811 to CASPER PHARMA LLC.

    Drugs@FDA application register · NDA012827 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA012827 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19900930.

    FDA National Drug Code directory · 71872-7292 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (7)

On the GLYCOPYRRONIUM, (2R,3'S)- label: indicated for what?


"Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Limitations of Use Glycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.": indications and usage on GLYCOPYRRONIUM, (2R,3'S)-'s label. DailyMed label · 1f266d77-4f9e-44c9-a000-2f8fea3ac80b · 2026-07-09

68 registered trials of GLYCOPYRRONIUM, (2R,3'S)- — at which phases?


Registered studies posting no result
38 of 68

68 registered studies of GLYCOPYRRONIUM, (2R,3'S)-: 21 phase4, 17 na, 15 phase2, 11 phase3, 10 phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01

404 with a PubMed record

Show the evidence
  • phase4
    21
  • na
    17
  • phase2
    15
  • phase3
    11
  • phase1
    10
  • completed
    53
5 more recorded rows
  • unknown
    9
  • terminated
    3
  • recruiting
    1
  • suspended
    1
  • withdrawn
    1

recorded 2026-09-01 · last checked 2026-09-04

4 of GLYCOPYRRONIUM, (2R,3'S)-'s trials stopped: safety, accrual/recruitment, other?


safety (1), accrual/recruitment (2) and other (1): GLYCOPYRRONIUM, (2R,3'S)-'s stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"PI left institution"; 4 of 68 registered studies

Show the evidence

Trial

  • NCT01588717
    terminated; "PI left institution"
  • NCT02574611
    withdrawn; "No reportable findings are possible. The PI/Co-PI were unable to recruit participants for this study. One participant was consented but did not undergo any study procedure."
  • NCT03322150
    terminated; "The research was terminated because the recruitment of the study subjects was not smooth and the overseas training of the investigator was scheduled."
  • NCT07541378
    suspended; "Recruitment was temporarily suspended pending additional funding and activation of additional study centers. The pilot phase has been completed and is currently being evaluated. The suspension was not related to safety concerns."

recorded 2026-09-01 · last checked 2026-09-04

Human studies of GLYCOPYRRONIUM, (2R,3'S)- used Glycopyrrolate (0.01mg/kg) — over how long?


Human studies of GLYCOPYRRONIUM, (2R,3'S)- used "Glycopyrrolate (0.01mg/kg)". ClinicalTrials.gov · 2026-09-01

9 recorded entries; human; also "Dose 1 of glycopyrrolate, 2.0% QD", "Dose 2 of glycopyrrolate, 3.0% QD", "Glycopyrrolate 0.2 MG"

Show the evidence

human

  • NCT01191398
    Glycopyrrolate (0.01mg/kg)
  • NCT02129660
    Dose 1 of glycopyrrolate, 2.0% QD
  • NCT02129660
    Dose 2 of glycopyrrolate, 3.0% QD
  • NCT04554589
    Glycopyrrolate 0.2 MG
  • NCT06545500
    Glycopyrrolate (85 μg)
  • NCT06545500
    Glycopyrrolate (42.5 μg)
3 more recorded rows
  • human NCT06545500
    Glycopyrrolate (14 μg)
  • human NCT07016412
    Glycopyrrolate 21.25 mcg
  • human NCT07016412
    Glycopyrrolate 42.5 mcg

recorded 2026-09-01 · last checked 2026-09-04

GLYCOPYRRONIUM, (2R,3'S)-'s half-life is 3.0 hours — which schedules were studied?


3.0 hours, the half-life GLYCOPYRRONIUM, (2R,3'S)-'s label states: "Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours." DailyMed label · 4741be85-3abb-4545-aba9-281f64d210ec · 2026-08-30

bioavailability 3% %.

Show the evidence
  • half life recorded_background.pharmacokinetics
    3.0 hours hours; Mean time to maximum plasma concentration for glycopyrrolate was 3.1 hours, and mean plasma half-life was 3.0 hours.
  • bioavailability recorded_background.pharmacokinetics
    3% %; The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%).

recorded 2026-08-30 · last checked 2026-09-04

Which 20 trials of GLYCOPYRRONIUM, (2R,3'S)- posted no result?


Posted no result
20 of 20 completed trials
Registrations
NCT01176851, NCT01176903, NCT01398111, NCT01476813, NCT02410460 and NCT02430272, and 14 more
Completion dates
oldest 2010-10; newest 2024-07-31
Show the evidence

Trial

  • NCT01176851
    2010-10
  • NCT01176903
    2011-08
  • NCT01398111
    2011-08
  • NCT01476813
    2013-07
  • NCT02410460
    2014-06
  • NCT02430272
    2014-12
14 further recorded trials
  • NCT02375217
    2015-10
  • NCT02622243
    2016-03
  • NCT02327923
    2016-04
  • NCT02953041
    2017-01-09
  • NCT03050242
    2017-05-19
  • NCT02613494
    2018-02-23
  • NCT03322098
    2018-05-15
  • NCT05997004
    2019-11-15
  • NCT04906655
    2021-05-20
  • NCT02872090
    2021-06-01
  • NCT03513406
    2023-03-07
  • NCT06237478
    2023-06-30
  • NCT05693246
    2024-07-30
  • NCT06045364
    2024-07-31

At the median, GLYCOPYRRONIUM, (2R,3'S)-'s trials enrolled 77 people — anything larger?


Median enrolment
77
Largest enrolment
22435
Registered trials counted
68
Where it is registered
Identifiers, relations and other names

The exact record

CAS number
51186-83-5
RxCUI
238212
InChIKey
ANGKOCUUWGHLCE-HKUYNNGSSA-N
Also called
Glycopyrrolate
Trade name
Glyrx-Pf, Robinul, Cuvposa, Dartisla, Lonhala Magnair Kit, Glycate, GLYCOPYRROLATE 1ML, Qbrexza, Zimbus Breezhaler, Riltrava Aerosphere, Bevespi Aerosphere
Salt form
Glycopyrrolate Oral Solution, Glyrx-Pf / Robinul / Glycopyrrolate Oral Solution / Cuvposa / Dartisla / Lonhala Magnair Kit, Glycopyrronium Tosylate
Also called
Glycopyrronium, GLYCOPYRRONIUM TOSILATE HYDRATE, GLYCOPYRRONIUM TOSILATE HYDRATE [JAN], GLYCOPYRRONIUM TOSYLATE MONOHYDRATE, GLYCOPYRRONIUM TOSYLATE [ORANGE BOOK], GLYCOPYRRONIUM TOSYLATE [USAN], Glycopyrronium tosylate monohydrate [WHO-DD]
Development code
DRM-04, DRM04
Component
Glycopyrrolate
Sources (6)

Sources

  • CLINICALTRIALS_SNAPSHOT K1:HTB34557V4 ·
  • ClinicalTrials.gov clinicaltrials.gov ·
  • drugsfda+ema drugsfda+ema ·
  • DailyMed label 1f266d77-4f9e-44c9-a000-2f8fea3ac80b ·
  • DailyMed label 4741be85-3abb-4545-aba9-281f64d210ec ·
  • Drugs@FDA K1:HTB34557V4 ·

ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.